Skip to main content
Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
Published Web Location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093998/pdf/ciy228.pdfNo data is associated with this publication.
Abstract
Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.